APOE4 Alzheimer’s Disease

LX1001 / LX1020 / LX1021 / Alzheimer’s

Alzheimer’s disease is a devastating condition affecting many patients and their families.

  • Fast Track Designation (FDA)
Programs: Indication: Target
Pre-clinical: Discovery Preclinical
Clinical: Phase I/II Phase II/III
CNS
Pre-clinical: Discovery Preclinical
Clinical: Phase I/II Phase II/III
LX1001 Alzheimer’s APOE2+ APOE2+
Pre-clinical: Discovery Preclinical
Clinical: Phase I/II Phase II/III
LX1021 Alzheimer’s Christchurch Christchurch
APOE2+
Pre-clinical: Discovery Preclinical
Clinical: Phase I/II Phase II/III
LX1020 Alzheimer’s APOE2+ /E4- APOE2+
APOE4-

Alzheimer’s disease is characterized by a complex underlying pathology in the CNS, including accumulation of Aß plaques, abnormal phosphorylation of tau, development of tau tangles, inflammation, and progressive loss of neurons, all of which combine to precipitate a progressive decline in cognitive function. Apoplipoprotein (APOE), a lipid transport protein, is the major transporter of cholesterol in the brain and is involved in synaptic integrity and plasticity, glucose metabolism, and cerebrovascular function.

DISEASE OVERVIEW

Alzheimer’s disease is characterized by a complex underlying pathology in the CNS, including accumulation of Aß plaques, abnormal phosphorylation of tau, development of tau tangles, inflammation, and progressive loss of neurons, all of which combine to precipitate a progressive decline in cognitive function. Apoplipoprotein (APOE), a lipid transport protein, is the major transporter of cholesterol in the brain and is involved in synaptic integrity and plasticity, glucose metabolism, and cerebrovascular function.

Presence of APOE4 is the most common genetic risk factor for Alzheimer’s disease. The prevalent APOE alleles are APOE4, APOE3 and APOE2, with the E4 allele increasing risk and reducing the age of onset and the E2 allele decreasing risk and markedly delaying the age of onset. APOE4 homozygous patients, individuals who have two copies of the E4 allele, are at the highest risk and are approximately fifteen times more likely to develop Alzheimer’s disease than the general population.

LX1001 MECHANISM

LX1001 is an AAV-based gene therapy candidate that is designed to express the protective APOE2 protein in the CNS of APOE4 homozygous patients to halt or slow the progression of Alzheimer’s disease.